Asset profile

Cemiplimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved — Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Featured trials

Research

Unlock featured-trial analysis

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

Upcoming events

(38 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (4)

August 2026 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-08-24 · NCT06161441 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2026 (1)

Phase 1/2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2026-09-30 · NCT05882734 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12 · NCT06623656 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (19)

January 2027 (2)

Phase 2Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Recruiting

Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Carcinoma in the LiverRecruiting

Est. primary completion 2027-01-30 · NCT06860815 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-02 · NCT06463665 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (3)

Phase 1/2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-04 · NCT06162572 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Recruiting

Est. primary completion 2027-04-29 · NCT06918132 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Advanced Solid MalignancyRecruiting

Est. primary completion 2027-04-30 · NCT06923761 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)

Phase 2Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma …Not yet recruiting

Est. primary completion 2027-05-01 · NCT06943664 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-05-20 · NCT06465329 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2027 (2)

Phase 1/2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-06 · NCT05864144 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-06-01 · NCT05317858 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

July 2027 (1)

Phase 3Carcinoma, Non-Small -Cell LungRecruiting

Est. primary completion 2027-07-31 · NCT06908304 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-08 · NCT06865339 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-09-28 · NCT05785767 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2027-09-30 · NCT05208944 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-10 · NCT07264673 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (3)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2027-12 · NCT06449313 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2027-12-01 · NCT07450183 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Recruiting

Est. primary completion 2027-12-31 · NCT06616584 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (5)

January 2028 (1)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2028-01-26 · NCT05557591 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-05 · NCT07418931 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2028 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2028-06 · NCT07360743 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2028 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-09 · NCT07020065 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2028-09 · NCT06656598 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (3)

March 2029 (1)

Phase 3Non-Small Cell Lung CancerRecruiting

Est. primary completion 2029-03 · NCT06931717 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2029 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2029-11-01 · NCT07720167 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2029-12-31 · NCT07274384 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (6)

January 2030 (2)

Phase 2Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2030-01 · NCT06219317 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2/3Non-Small Cell Lung CancerActive not recruiting

Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2030 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-06-25 · NCT07603856 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2030 (2)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2030-09 · NCT07001618 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting

Est. primary completion 2030-09-01 · NCT07746388 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2030 (1)

Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting

Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2031 (1)

December 2031 (1)

Phase 2Non-Small Cell Lung CancerRecruiting

Est. primary completion 2031-12-30 · NCT06917573 · CT.gov ↗

What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.